NASDAQ:DFFN - Diffusion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.50
  • Forecasted Upside: 343.04 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.79
▼ -0.027 (-3.30%)

This chart shows the closing price for DFFN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Diffusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DFFN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DFFN

Analyst Price Target is $3.50
▲ +343.04% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Diffusion Pharmaceuticals in the last 3 months. The average price target is $3.50, with a high forecast of $3.50 and a low forecast of $3.50. The average price target represents a 343.04% upside from the last price of $0.79.

This chart shows the closing price for DFFN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Diffusion Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021HC WainwrightReiterated RatingHoldLow
11/17/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
8/12/2020HC WainwrightReiterated RatingBuy$3.50High
3/19/2020HC WainwrightReiterated RatingBuy$3.50High
12/18/2019HC WainwrightLower Price TargetBuy$10.00 ➝ $3.50Medium
3/20/2019HC WainwrightBoost Price TargetBuy$10.00Low
11/15/2018HC WainwrightSet Price TargetBuy$15.00High
8/20/2018HC WainwrightReiterated RatingBuy$18.75Medium
4/16/2018HC WainwrightSet Price TargetBuy$15.00High
3/21/2018HC WainwrightInitiated CoverageBuy ➝ Buy$18.75High
(Data available from 6/24/2016 forward)
Diffusion Pharmaceuticals logo
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Read More

Today's Range

Now: $0.79
Low: $0.77
High: $0.80

50 Day Range

MA: $0.71
Low: $0.60
High: $0.82

52 Week Range

Now: $0.79
Low: $0.60
High: $1.85

Volume

949,160 shs

Average Volume

4,913,862 shs

Market Capitalization

$80.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Diffusion Pharmaceuticals?

The following sell-side analysts have issued reports on Diffusion Pharmaceuticals in the last twelve months: HC Wainwright.
View the latest analyst ratings for DFFN.

What is the current price target for Diffusion Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Diffusion Pharmaceuticals in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 343.0%. HC Wainwright has the highest price target set, predicting DFFN will reach $3.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.50 for Diffusion Pharmaceuticals in the next year.
View the latest price targets for DFFN.

What is the current consensus analyst rating for Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DFFN, but not buy more shares or sell existing shares.
View the latest ratings for DFFN.

What other companies compete with Diffusion Pharmaceuticals?

How do I contact Diffusion Pharmaceuticals' investor relations team?

Diffusion Pharmaceuticals' physical mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company's listed phone number is 434-220-0718 and its investor relations email address is [email protected] The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com.